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https://doi.org/10.1016/j.jaad.2019.04.040Secukinumab demonstrates
sustained efficacy in clearing skin
and improving patient-reported
outcomes in patients with moderate-
to-severe psoriasis through 2 years
of treatment: Results from the
CLEAR studyTo the Editor: Secukinumab is a fully human mono-
clonal antibody that selectively neutralizes interleukin
17A, a key cytokine involved in the development of
psoriasis.1 Secukinumab has shown long-lasting effi-
cacy and safety in the complete spectrum of psoriatic
disease, including disease localized to nails, scalp,
palms and soles, and joints (peripheral and axial
arthritis).1-3 Given the chronic and relapsing nature of
psoriasis, long-term data might help to fully charac-
terize the efficacy and safety profile of secukinumab
as well as its impact on quality of life.ª 2019 by the American Academy of Dermatology, Inc. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The CLEAR study (NCT02074982) was a phase 3b,
head-to-head, randomized, double-blind study on
the efficacy and safety of secukinumab compared
with ustekinumab over 52 weeks of treatment in
adult patients with moderate-to-severe psoriasis.
Results from the 16-week and 52-week time points
showed higher and sustained superior efficacy of
secukinumab versus ustekinumab; secukinumab
use also provided a greater improvement in
patient-reported outcomes (PROs), and its safety
profile was comparable with ustekinumab.4,5
Patients from the secukinumab arm who completed
52 weeks of treatment and consented to continue
in the open-label extension phase received
secukinumab 300mg at week 52, followed by dosing
every 4 weeks to week 100. Methods for the CLEAR
study have been described in detail elsewhere.4,5
Here, we present the efficacy, safety, and PROs from
a total of 2 years of secukinumab treatment.
Of 337 patients randomized to receive secukinu-
mab 300 mg, 312 completed the 52-week study, and
303 patients entered the extension phase. In total,
277 patients completed the 2-year extension study.
Irrespective of the analysis (observed, multiple
imputation, modified nonresponder imputation),
Psoriasis Area and Severity Index 75, 90, and 100,
and Investigator’s Global Assessment 2011 modified
version 0/1 response rates with secukinumab treat-
ment at week 16 were sustained up to year 2
(Table I). A similar trend was seen for the
Dermatology Life Quality Index 0/1 response.
Further, the mean scores for patient assessment of
psoriasis-related pain, itching, and scaling severity
remained low up to year 2 of secukinumab treatment
(Table I). Secukinumab treatment resulted in a mean
percentage of change of85.6% for pain,77.6% for
itching, and81.9% for scaling from baseline to year
2. Furthermore, a high proportion of patients
achieved complete relief (score 0) of psoriasis-
related pain, itching, and scaling at week 16, and
the response was sustained up to year 2 (Table I).
Among adverse events of interest, Candida
infections were reported in 24 (7.2%) patients (all
events were nonserious and did not lead to study
discontinuation) and malignant or unspecified
tumors were reported in 5 (1.5%) patients.
Neutropenia was reported in 1 patient during the
first year of treatment (mild severity, not associated
with any infection or opportunistic infections).
Overall, there was no increase in the rate of adverse
events, and no new or unexpected signals were
identified (Table II).
In conclusion, the 2-year results from the CLEAR
study confirm the sustained efficacy and improved
PROs provided by secukinumab in patients with
Table I. Efficacy and patient-reported outcomes through year 2 of secukinumab 300-mg treatment
Efficacy
Week 16 Year 1 Year 2
As observed MI mNRI As observed MI mNRI As observed MI mNRI
PASI 75 94.5 (310/328) 94.2 (315/334) 93.1 (311/334) 93.7 (282/301) 92.4 (308/334) 91.6 (306/334) .6 (138/154) 83.1 (278/334) 83.8 (280/334)
PASI 90 80.5 (264/328) 80.1 (268/334) 79.0 (264/334) 78.4 (236/301) 76.3 (255/334) 74.9 (250/334) .7 (115/154) 62.6 (209/334) 66.8 (223/334)
PASI 100 45.1 (148/328) 45.0 (150/334) 44.3 (148/334) 48.2 (145/301) 45.8 (153/334) 44.9 (150/334) .4 (73/154) 36.9 (123/334) 38.6 (129/334)
IGA mod 2011 0/1 84.5 (277/328) 84.3 (282/334) 83.2 (278/334) 81.7 (246/301) 80.2 (268/334) 78.1 (261/334) .8 (106/154) 66.5 (222/334) 66.5 (222/334)
PROs
Week 16 Year 1 Year 2
As observed LOCF As observed LOCF As observed LOCF
DLQI 0/1 72.2 (236/327) 71.9 (238/331) 71.9 (210/292) 71.6 (237/331) 66.0 (105/159) 65.9 (218/331)
Pain, mean score (m) 0.8 (327) 0.8 (333) 0.8 (292) 0.8 (333) 0.7 (159) 0.9 (333)
Itching, mean score (m) 1.2 (327) 1.2 (333) 1.2 (292) 1.3 (333) 1.3 (159) 1.5 (333)
Scaling, mean score (m) 0.8 (327) 0.8 (333) 1.0 (292) 1.0 (333) 1.1 (159) 1.3 (333)
Complete relief*
As observed
Week 16 Year 1 Year 2
Pain 69.4 (177/255) 67.1 (151/225) 70.9 (90/127)
Itching 49.7 (157/316) 48.9 (138/282) 47.4 (72/152)
Scaling 61.2 (197/322) 53.3 (153/287) 54.8 (86/157)
Values are % (n/m), except where indicated. Efficacy variables and PROs were primarily assessed by using observed values (no imputation of issing values). In addition, the MI and mNRI methods
were used as sensitivity analyses for efficacy variables, and the LOCF method was used for PROs. Missing values were imputed in MI analysi y using the missing at random assumption. In mNRI
analyses, the missing values were imputed as nonresponse regardless of the reason for missing data, except if the patient had been a respond r for 2 consecutive visits before the study completion
or discontinuation or if the patient had been a responder at visits both before and after the missed visit. In LOCF analyses, the last available m asurement for each patient was carried forward to all
later visits. DLQI, Dermatology Life Quality Index; IGA mod 2011, Investigator Global Assessment 2011 modified version; LOCF, last observa n carried forward; m, number of patients evaluable;
MI, multiple imputation; mNRI, modified nonresponder imputation; n, number of patients with response; PASI, Psoriasis Area Severity Index PROs, patient-reported outcomes.















































N = 335, n (%)
Up to year 1,
N = 335, n (%)
From[1 year to end
of study, N = 307, n (%)
Any adverse event 299 (89.3) 286 (85.4) 198 (64.5)
Serious adverse event 41 (12.2) 32 (9.6) 13 (4.2)
Death 0 (0) 0 (0) 0 (0)
Adverse events leading to study treatment discontinuation 18 (5.4) 11 (3.3) 8 (2.6)
Primary system organ class
Infections and infestations 231 (69.0) 197 (58.8) 137 (44.6)
Most common ($5%)*
Nasopharyngitis 96 (28.7) 77 (23.0) 39 (12.7)
Headache 50 (14.9) 40 (11.9) 18 (5.9)
Upper respiratory tract infection 42 (12.5) 31 (9.3) 23 (7.5)
Arthralgia 36 (10.7) 26 (7.8) 13 (4.2)
Influenza 33 (9.9) 22 (6.6) 12 (3.9)
Oropharyngeal pain 32 (9.6) 28 (8.4) 4 (1.3)
Back pain 29 (8.7) 21 (6.3) 11 (3.6)
Pruritus 25 (7.5) 20 (6.0) 6 (2.0)
Diarrhea 23 (6.9) 23 (6.9) 4 (1.3)
Psoriasis 22 (6.6) 12 (3.6) 11 (3.6)
Cough 21 (6.3) 13 (3.9) 10 (3.3)
Bronchitis 20 (6.0) 13 (3.9) 9 (2.9)
Fatigue 20 (6.0) 18 (5.4) 2 (0.7)
Eczema 19 (5.7) 15 (4.5) 5 (1.6)
Conjunctivitis 18 (5.4) 16 (4.8) 4 (1.3)
Select adverse events of interest
Candida infectionsy 24 (7.2) 19 (5.7) 8 (2.6)
Oral candidiasis 15 (4.5) 12 (3.6) 5 (1.6)
Vulvovaginal candidiasis 4 (1.2) 3 (0.9) 1 (0.3)
Genital candidiasis 2 (0.6) 1 (0.3) 1 (0.3)
Esophageal candidiasis 2 (0.6) 2 (0.6) 0 (0)
Balanitis candida 1 (0.3) 0 (0) 1 (0.3)
Candida infection 1 (0.3) 1 (0.3) 0 (0)
Oropharyngeal candidiasis 1 (0.3) 1 (0.3) 0 (0)
Skin candida 1 (0.3) 1 (0.3) 0 (0)
Malignant or unspecified tumorsz 5 (1.5) 4 (1.2) 1 (0.3)
Malignant melanoma in situ 2 (0.6) 2 (0.6) 0 (0)
Basal cell carcinoma 1 (0.3) 0 (0) 1 (0.3)
Keratoacanthoma 1 (0.3) 1 (0.3) 0 (0)
Lung adenocarcinoma 1 (0.3) 1 (0.3) 0 (0)




J AM ACAD DERMATOL
VOLUME 81, NUMBER 6
Research Letters 1407moderate-to-severe plaque psoriasis, while main-
taining a favorable safety profile.
The authors thank Dhaval Gupta, MPH (Novartis
Healthcare Pvt Ltd, India), and Jackie L. Johnson, PhD
(Novartis Ireland Ltd), for providing medical writing
support, which was funded by Novartis Pharma AG,
Basel, Switzerland, in accordance with Good Publication
Practice guidelines (http://www.ismpp.org/gpp3).
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https://doi.org/10.1016/j.jaad.2019.04.045Association of particulate matter air
pollution and itch: A digital
epidemiology approachFig 1. Air pollution and Google search volume index
(SVI) for 49 States in the United States in 2014. PM2.5.
Particulate matter no larger than 2.5 m.To the Editor: Ambient air pollution secondary to
industrialization is a growing health concernwith the
potential to cause exposure-related skin toxicity.1
Among skin conditions, itch may be especially sus-
ceptible to environmental modulation, given that
free nerve endings of sensory neurons are located in
the epidermis.2 Although several air pollutants are
postulated to affect health, one well-studied marker
of air quality is atmospheric particulate matter no
larger than 2.5 m (PM2.5). Fine particulate matter of
this size has important health effects, given its ability
to penetrate the body systemically and serve as a
carrier of pathogens and toxins.1 We thus
hypothesized that increasing levels of PM2.5 are
associated with increased population-level search
interest in itch as a proxy for itch sensation.
Google Trends is an open-access database
aggregating search queries across various regions
that has been used for health care research, with
successful validation against external data sets.3
Search volume index (SVI) is a normalized value
ranging from 0 to 100 that indicates the quantity of
queries for a searched topic relative to all other
queries within the given time frame. SVI data wereevaluated within the United States in 2014 for the
term itch, and for purposes of comparison, SVI data
for the term acne were evaluated. We obtained data
on annual state averages for PM2.5 for 2014 from the
US Centers for Disease Control and Prevention’s
National Environmental Public Health Tracking
Network. Multivariate linear regression was
conducted to examine the association between SVI
for skin-related complaints and PM2.5 adjusted for
climate, population density, and percentage of
population located in urban areas.
